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Background/aim: Hyperthyroidism causes hemodynamic changes that are associated with adverse cardiovascular outcomes. Twentyfour-hour ambulatory blood pressure monitoring recordings provide us with some essential data: BP variability and ambulatory
arterial stiffness index (AASI). In this study, we aimed to investigate AASI and short-term BP variability in both overt and subclinical
hyperthyroidism and their relationship with thyroid hormones.
Materials and methods: We enrolled 36 patients with subclinical hyperthyroidism, 23 patients with overt hyperthyroidism, and 25
healthy euthyroid controls. ABPM recording was performed for 24 h for all patients.
Results: There were no statistically significant differences among the overt hyperthyroidism, subclinical hyperthyroidism, and control
groups in terms of AASI (0.43 ± 0.15, 0.38 ± 0.12, 0.42 ± 0.13, respectively; P = 0.315). Variability of diastolic BP was significantly
higher in patients with overt hyperthyroidism than in patients with subclinical hyperthyroidism (14.8 ± 2.6 vs. 12.8 ± 2.5%, P = 0.023).
There were significant positive correlations between AASI and fT3 (r = 0.246, P = 0.02) and fT4 (r = 0.219, P = 0.04) while TSH was not
correlated with AASI (r = 0.023, P = 0.838). After adjusting for confounders, age, 24-h systolic and diastolic BP, variability of systolic and
diastolic BP, and fT4 were independent predictors of AASI (r2 = 0.460, P < 0.001).
Conclusion: Although AASI did not differ between overt and subclinical hyperthyroidism, there was a positive relationship between
AASI and free thyroid hormone levels. Furthermore, short-term BP variability was higher in overt hyperthyroidism than in subclinical
hyperthyroidism.
Key words: Ambulatory arterial stiffness index, blood pressure variability, hyperthyroidism

1. Introduction
Thyroid hormones interact with endothelial function,
vascular reactivity, renal hemodynamics, and the renin–
angiotensin system (1). Thus, thyroid disorders cause certain
hemodynamic changes leading to elevated blood pressure
(BP) (2). Overt hyperthyroidism, whether endogenous or
exogenous in origin, is associated with increased cardiac
output, increased resting heart rate, contractility, ejection
fraction, and blood volume with decreased systemic
vascular resistance (3). Higher heart rate, frequent atrial
premature beats, increased prevalence of atrial fibrillation,
increased left ventricular mass, and diastolic dysfunction
are also reported in subclinical hyperthyroidism. Several
studies showed that there is an association between overt
and subclinical hyperthyroidism and increased arterial
stiffness, as well as impaired vascular elasticity (4,5).
Twenty-four-hour
ambulatory
blood
pressure
monitoring (ABPM) is a noninvasive way of reviewing
* Correspondence: ozturhan78@hotmail.com

arterial changes associated with cardiovascular risk.
Ambulatory arterial stiffness index (AASI) is a parameter
based on the relationship between diastolic and systolic blood
pressure derived from ABPM recordings and was recently
proposed as a relatively easy way to measure arterial stiffness
(6). Although there is quite some debate about the use of
AASI as a marker for arterial stiffness, recent prospective
studies showed that elevated AASI is an independent
predictor for cardiovascular mortality and stroke and is
a valuable tool for cardiovascular risk stratification (7,8).
Short-term blood pressure variability is defined as the
standard deviation or coefficient variation from the mean
BP in 24-h ABPM recordings (9). Variability may reflect
alterations in cardiovascular regulatory mechanisms, which
in turn may also affect cardiovascular prognosis (10).
In this study, we aimed to investigate how AASI and
BP variability change in patients with overt and subclinical
hyperthyroidism.
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2. Methods
2.1. Study groups
We enrolled 59 patients with hyperthyroidism and 25
healthy euthyroid controls in the study. None of the
participants had a medical history of chronic disease such
as hypertension, diabetes mellitus, chronic renal failure,
chronic hepatic disease, and cardiovascular diseases.
The hyperthyroid group included 36 patients with
subclinical hyperthyroidism and 23 patients with overt
hyperthyroidism. Overt hyperthyroidism was defined
as suppressed TSH with high free fT3 (fT3) and/or free
T4 (fT4) levels, which was caused by Graves’ disease in
all cases. Subclinical hyperthyroidism was defined as
suppressed TSH with normal fT3 and fT4 levels on two
occasions in 6 months. Patients with both endogenous
and exogenous subclinical hyperthyroidism were included
in the study. The etiologies of endogenous subclinical
hyperthyroidism were toxic adenoma or toxic multinodular
goiter. For exogenous subclinical hyperthyroidism,
patients with differentiated thyroid cancer under TSH
suppression due to levothyroxine therapy were included.
Among the 23 patients with subclinical hyperthyroidism
12 had toxic adenoma or toxic multinodular goiter and
11 had exogenous subclinical hyperthyroidism due to
levothyroxine treatment. Median duration of levothyroxine
treatment of the patients with differentiated thyroid cancer
was 6 (2–8) years and the mean daily dose of levothyroxine
was 125 µg/day.
The study protocol was approved by the ethics
committee of Gazi University, and the study was carried
out in accordance with the principles of the Declaration of
Helsinki. All subjects gave their written informed consent
before participating in this study.
2.2. Laboratory measurements
Serum TSH, fT3 and fT4 concentrations were measured
with chemiluminescent immunoassay on an automatic
analyzer (Architect, Abbott Diagnostics, Abbott Park, IL,
USA). Normal ranges were as follows: fT3 (1.71–3.71 pg/
mL), fT4 (0.76–1.89 ng/dL), and TSH (0.35–4.94 mIU/L).
2.3. Measurement of BP variability and AASI
Office BP was obtained by calculating the mean of two
separate measurements with at least a 5-min interval. BP
was measured in every patient during the clinic visit by
the same nurse using a mercury sphygmomanometer,
on the left arm, after 5 min of rest. ABPM recording was
performed for 24 h using Spacelabs model 90207 monitors
(Issaquah, WA, USA), on a day of standard activity, with
an adequate cuff size of the patient’s arm. The records of
readings considered to be valid were ≥80% of the total. The
monitor was programmed for obtaining blood pressure
measurements every 20 min during the waking period
and every 30 min during the resting period. Individual
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correction was made for the waking and sleeping hours as
reported by the patient.
Systolic and diastolic BP variability were expressed
by the coefficient of variation (CV) of systolic or diastolic
measurements, defined by using relative changes (CV =
100 × s.d./mean). AASI is defined as 1 – (diastolic-onsystolic slope), wherein the slope was determined from a
DBP vs. SBP plot by a standard regression procedure (6).
Nocturnal dipping (%) was defined as the percentage
decrease in nocturnal systolic BP compared with daytime
systolic BP. When patients showed nocturnal dipping of
less than 10%, they were defined as “nondippers”.
2.4. Statistical analysis
Analyses were performed using SPSS version 15.0 for
Windows (SPSS, Chicago, IL, USA) and GraphPad
Prism software version 6.0 (GraphPad, San Diego, CA,
USA). Continuous data were presented as means ±
standard deviation or median [minimum–maximum],
as appropriate. Chi-square (categorical variables) and
ANOVA/Kruskal–Wallis (continuous variables) tests
were used to assess differences between groups. Post
hoc comparisons were carried out using the Mann–
Whitney U test for nonparametric variables and Tukey’s
test for parametric variables. Bonferroni correction was
applied for multiple comparisons of nonparametric
variables. Pearson correlation analysis was used to test for
correlation of normal variables considered to be associated
with AASI, whereas Spearman correlation analysis was
used for variables not showing a normal distribution.
Multiple linear regression analysis was used to determine
predictors among risk factors considered to be related to
AASI in the entire population. P < 0.05 was considered to
be statistically significant.
3. Results
The demographic, biochemical, and anthropometric
characteristics of the patients included in the study are
given in Table 1. Mean age of all study subjects was 45.2 ±
10.5 years and 61 (72.6%) of the participants were women.
Patients with overt hyperthyroidism were younger than
patients with subclinical hyperthyroidism and controls
(38.5 ± 9.7 vs. 47.8 ± 10.2 and 47.7 ± 9.0 years, respectively;
P = 0.001) (Table 1). The groups were similar in terms of
sex distribution (P = 0.295) (Table 1).
In patients with overt and subclinical hyperthyroidism
TSH levels were lower and fT4 levels were higher compared
with the control subjects (P < 0.001 for TSH; P < 0.001 for
fT4), (Table 1). Serum fT3 levels were significantly higher
in patients with overt hyperthyroidism compared to those
with subclinical hyperthyroidism and the controls (P <
0.001) (Table 1).
Heart rate of the patients with overt hyperthyroidism
was significantly higher than that of patients with
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Table 1. Demographic, ambulatory blood pressure monitoring, and biochemical characteristics of the study subjects.

Age (years)

Ohyper (n = 23)

Shyper (n = 36)

Control (n = 25)

P

38.5 ± 9.8

47.8 ± 10.2

47.8 ± 9

0.001a,b

Sex (male) [n, (%)]

8 (34.8)

11(30.6)

4 (16)

0.295

Heart rate (beats/min)

91 ± 12

76 ± 7

73 ± 6

<0.001a,b

Office systolic BP (mmHg)

130.3 ± 10.3

120.3 ± 9.5

123.6 ± 10.4

0.002a

Office diastolic BP (mmHg)

81.0 ± 9.2

76.4 ± 6.4

77.1 ± 8.8

0.096

24-h systolic BP (mmHg)

125.4 ± 7.7

117.9 ± 9.0

119.0 ± 9.0

0.005a,b

24-h diastolic BP (mmHg)

72.2 ± 5.6

73.4 ± 6.1

72.2 ± 5.6

0.592

24-h systolic CV(%)

9.7 ± 2.0

9.2 ± 1.6

10.3 ± 2.0

0.077

24-h diastolic CV (%)

14.8 ± 2.6

12.8 ± 2.5

14.1 ± 3.3

0.023a

Daytime systolic BP (mmHg)

128.0 ± 8.7

118.5 ± 8

122.6 ± 9.4

0.001a

Daytime diastolic BP (mmHg)

75.2 ± 6.4

76.2 ± 10.0

77.5 ± 7.3

0.145

Night-time systolic BP (mmHg)

119.0 ± 7.2

108.5 ± 11.1

112.0 ± 10.2

0.001a,b

Night-time diastolic BP (mmHg)

66.4 ± 5.9

66.4 ± 5.8

67.0 ± 9.3

0.838

Nondipper [n, (%)]

18 (78)

24 (75)

18 (72)

0.882

AASI

0.43 ± 0.15

0.38 ± 0.12

0.42 ± 0.13

0.315

fT3 (pg/mL)

14.2 ± 7.64

3.09 ± 0.33

2.94 ± 0.28

<0.001a,b

3.39 (1.57–7.77)

1.38 (0.38–1.70)

1.17 (0.90–1.59)

<0.001a,b,c

0.005 (0.005–0.11)

0.11 (0.001–0.34)

1.32 (0.47–3.79)

<0.001a,b,c

fT4 (ng/mL) ǂ
TSH (mIU/L)

ǂ

ǂ: Data are given as median (minimum–maximum) or as mean ± SD, Ohyper: overt hyperthyroidism, Shyper: subclinical hyperthyroidism,
BP: blood pressure, CV: coefficient of variation, AASI: ambulatory arterial stiffness index, fT4: free T4, fT3: free T3, TSH: thyroid
stimulating hormone
a: Ohyper vs. shyper by the appropriate statistical test.
b: Ohyper vs. control by the appropriate statistical test.
c: Shyper vs. control by the appropriate statistical test.

subclinical hyperthyroidism and the controls (91 ± 12 vs.
76 ± 7 and 73 ± 6/min, respectively; P < 0.001).
Office systolic BP measurements were significantly
higher in patients with overt hyperthyroidism than in
patients with subclinical hyperthyroidism and the controls
(130.3 ± 10.3 vs. 120.3 ± 9.5 and 123.6 ± 10.4 mmHg,
respectively; P = 0.002). Twenty-four-hour systolic BP
measurements in ABPM recordings were significantly
higher in patients with overt hyperthyroidism compared
with patients with subclinical hyperthyroidism and
the controls (125.4 ± 7.7 vs. 117.9 ± 9.0 and 119.0 ± 9.0
mmHg, respectively; P = 0.005). Night-time systolic
BPs in ABPM recordings were significantly higher in
patients with overt hyperthyroidism than in patients with
subclinical hyperthyroidism and the controls (119.0 ± 7.2
vs. 108.5 ± 11.1 and 112.0 ± 10.2 mmHg respectively; P =
0.001). Day-time systolic BPs in ABPM recordings were
significantly higher in patients with overt hyperthyroidism
than in patients with subclinical hyperthyroidism (128.0
± 8.7 vs. 118.5 ± 8 mmHg, P = 0.001). However, there
was no significant difference between patients with overt

hyperthyroidism and the control group in terms of daytime systolic BPs in ABPM recordings (128.0 ± 8.7 vs.
122.6 ± 9.4 mmHg, P = 0.08).
Variability of diastolic BP, as expressed by 24-h
diastolic CV, was significantly higher in patients with
overt hyperthyroidism than in patients with subclinical
hyperthyroidism (14.8 ± 2.6 vs. 12.8 ± 2.5%, P = 0.023).
There were no statistically significant differences among
the overt hyperthyroidism, subclinical hyperthyroidism,
and control groups in terms of AASI (0.43 ± 0.15, 0.38 ±
0.12, 0.42 ± 0.13, respectively; P = 0.315). After adjustment
for age, the groups were still similar for AASI (P = 0.104).
When the whole group was analyzed, there were
significant positive correlations between AASI and fT3 (r
= 0.246, P = 0.02) and fT4 (r = 0.219, P = 0.04), while TSH
was not correlated with AASI (r = 0.023, P = 0.838). After
adjusting for confounders, age, 24-hsystolic and diastolic
BP, variability of systolic and diastolic BP (24-h systolic
and diastolic CV), and fT4 were independent predictors
of AASI (r2 = 0.460, P < 0.001). Table 2 shows the results of
multiple regression analysis.
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Table 2. Independent predictors of AASI in a multiple regression
analysis best fitting model (R2 = 0.460).
β

P

Age (years)

0.003

0.044

Sex

0.039

0.182

24-h systolic BP (mmHg)

0.008

<0.001

24-h diastolic BP (mmHg)

–0.012

<0.001

24-h systolic CV (%)

0.040

0.001

24-h diastolic CV (%)

–0.044

<0.001

Nondipper

–0.009

0.758

fT4 (ng/mL)

0.020

0.045

BP: blood pressure, CV: coefficient of variation, AASI: ambulatory
arterial stiffness index, fT4: free T4

4. Discussion
In this study, we found a significant relationship
between AASI and free thyroid hormones; however,
AASI did not differ between patients with overt and
subclinical hyperthyroidism and control subjects.
Variability in diastolic BP was higher in patients with
overt hyperthyroidism than in patients with subclinical
hyperthyroidism in our study.
Thyroid disorders are related to increased prevalence
of cardiovascular disease and atherosclerosis (1). Overt
hyperthyroidism is a risk factor for atrial fibrillation,
stroke, and cardiovascular mortality (11). Arterial stiffness
is an early and important risk factor for development
of cardiovascular diseases (12). Some studies have
investigated the possible effects of thyroid hormone excess
on arterial stiffness with different measurement methods
(13). However, the association between hyperthyroidism
and arterial stiffness is still not clear due to controversial
results of the previous studies in the literature. Palmieri
et al. found that arterial stiffness was increased in overt
hyperthyroidism (14). Similarly, aortic stiffness was
reported to be increased in patients with exogenous
subclinical hyperthyroidism (5). Inaba et al. showed
a significant decrease in stiffness index in the carotid
artery after maintaining euthyroid state in patients with
overt hyperthyroidism, but this study did not include
a control group (15). In contrast, Obuobie et al. showed
decreased augmentation of central arterial pressure and
reduced arterial stiffness in untreated thyrotoxicosis
(16). A cross sectional study found that stiffness of the
common carotid artery, which was calculated with a
different method from ours, was not different in patients
with hyperthyroid Graves’ disease compared to euthyroid
controls, which is in line with our findings. In that study,
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there were strong correlations between arterial stiffness
and thyroid hormone levels, which is also similar to our
results (17). The distinctive feature of our study is that we
also included patients with subclinical hyperthyroidism
and found that these patients also had AASI similar to the
control group. To the best of our knowledge, this is the first
study that investigated AASI in both overt and subclinical
hyperthyroid states. Regarding the possible mechanisms
for similar AASI in hyperthyroid and control groups,
Kips et al. found that both vascular resistance and heart
rate were inversely related to AASI (18). Hyperthyroidism
increases heart rate and is associated with decreased
systemic vascular resistance. These opposing mechanisms
may have a confounding effect on AASI and might explain
the lack of difference in terms of AASI between overt and
subclinical hyperthyroid and control groups in our study.
In our study, we also found significant positive
correlations between AASI and free thyroid hormones.
Our data are consistent with a previous study by Delitala
et al., who found a relationship between fT4 and pulse
wave velocity but not with TSH (19). These findings, taken
together, suggest that excess thyroid hormones may have
some unfavorable effects on arterial stiffness in the long
term. Future studies with larger patient groups on this
topic are needed.
Age is a major determinant of arterial stiffness in large
elastic arteries and stiffness increases especially after the
age of 55 (20). The patients with overt hyperthyroidism
in our study were younger due to Graves’ disease, which
peaks in the third to fourth decade of life (21). Although
they were younger than subclinical hyperthyroid patients
and euthyroid controls, we did not observe any difference
in terms of AASI between the groups. However, there was
a positive correlation between fT3 and fT4 and AASI in
patients with overt hyperthyroidism despite the younger
age of these patients.
BP variability, expressed as CV, was an independent
predictor of AASI in our study. This result suggests that
AASI may not only measure arterial stiffness but may
also represent BP variability. Further studies are needed
to evaluate the alteration of BP variability and AASI after
maintaining euthyroidism.
Our results also showed that BP measurements
obtained instantly at the office, by ABPM throughout the
24 h, and BP variability calculated through ABPM are
higher in overt hyperthyroidism compared to subclinical
hyperthyroidism.
Short-term BP variability is estimated from ABPM
recordings by calculating 24 h BP SD or CV (22).
Variability of diastolic BP was higher in patients with
overt hyperthyroidism than in patients with subclinical
hyperthyroidism in our study. The pathophysiological
mechanisms of BP variability in hyperthyroidism
remain unclear. Increased short-term BP variability in
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overt hyperthyroidism might be explained by increased
sympathetic nerve activity and decreased systemic
vascular resistance.
There are scarce data about 24-h BP recordings in
patients with hyperthyroidism. A previous study showed
that the average 24-h BP measurements in patients with
hyperthyroidism were similar to those in euthyroid subjects
(23). Iglesias et al. reported higher systolic BP in patients
with overt hyperthyroidism compared with euthyroid
controls and systolic BP decreased after normalization of
thyroid hormone levels (24). In our study, in accordance
with previous studies, overt hyperthyroid patients had
higher systolic BP than euthyroid subjects whereas the
groups were similar for diastolic BP throughout the 24-h
period. We could not find any difference between patients
with subclinical hyperthyroidism and control subjects in
terms of systolic and diastolic BP. Our result is consistent
with a metaanalysis by Cai et al., which indicated that

subclinical hyperthyroidism is not associated with
increased BP (25). These findings taken together suggest
that blood pressure alterations are more noticeable in
overt hyperthyroidism.
The major limitations of our study are the relatively
small sample size and the heterogeneity of the etiologies of
the patients with subclinical hyperthyroidism.
In conclusion, our study showed that while there was
a positive relationship between AASI and free thyroid
hormones, AASI did not differ between overt and
subclinical hyperthyroidism and short-term BP variability
was higher in overt hyperthyroidism than in subclinical
hyperthyroidism. Further studies are needed to enlighten
the possible relation between arterial stiffness and excess
thyroid hormones. Larger prospective studies investigating
the alteration in BP variability and AASI after maintaining
euthyroidism may potentially broaden our understandings
about the vascular effects of thyroid hormones.
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